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Abstract
Background: Cervical cancer is the third most common cancer in Brazil and has a high potential for prevention
and cure. The prevalence of invasive and preinvasive disease in women with cytological diagnosis of high-grade
lesion – cannot exclude microinvasion (HSIL-micro) is not known.
Methods: This cross-sectional study used a cytology lab database to identify women with HSIL-micro and HSIL
referred to two colposcopic units from June 2006 to December 2012. For each woman with HSIL-micro, four
women with cytologic diagnosis of HSIL who met the inclusion criteria were identified. Data were obtained from
review of medical records.
Results: Forty-seven patients with report of HSIL-micro and 188 patients with report of HSIL were included.
The final diagnoses revealed a frequency of preinvasive lesions of 31.9 % (15/47) and 59.6 % (112/188) in
patients with HSIL-micro and HSIL, respectively, while the frequency of invasive disease was 63.8 % (30/47) and 11.7 %
(22/188), respectively. The HSIL-micro group showed prevalence of preinvasive or invasive disease 6.5 times greater
(95 % CI = 1.6-5.7) and, for invasive disease, 2.4 times greater (95 % CI = 1.7-3.6) than the HSIL group.
Conclusion: Higher risk of preinvasive and invasive lesions in women with cytologic diagnosis of HSIL-micro
reinforces recommendations for immediate investigation.
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Background
Cervical cancer is the fourth most common cancer in
women, and the seventh overall, with an estimated
528,000 new cases in 2012. Also 266,000 deaths from
cervical cancer were estimated worldwide in 2012, ac-
counting for 7.5 % of all female cancer deaths http://
globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
The main prevention strategy is based on screening pro-
grams using the Pap smear and reference for colposcopy
in positive cases, according to specific guidelines. Almost
85 % of cancer cases occur in developing countries, where
screening is less effective. The highest incidence rates
are observed in Latin America and in the Caribbean,
in sub-Saharan Africa, as well as in south and south-
east Asia http://globocan.iarc.fr/old/FactSheets/cancers/
cervix-new.asp [1].
Cervical cancer is the third most common cancer
among women in Brazil. In 2014, 15,590 new cases of
cervical cancer were expected, with an estimated risk of
15.33 cases per 100,000 women [2].
Screening of cervical cancer and its precursors in
Brazil is performed by a cervical Pap smear, every 3 years
in 25–64 year-old women, in an opportunistic manner
[2]. The nomenclature for cytologic reports [3] is based
on the Bethesda Classification, which is the most
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accepted and worldwide used nomenclature for Pap
smear reports. However, in Brazil, a diagnostic category
not found in the original Bethesda System, the “High-
Grade Squamous Intraepithelial Lesion cannot exclude
microinvasion” (HSIL-micro) is also possible. This cat-
egory can be considered analogous to the situation fore-
seen in the Bethesda System, in which it is possible to
register the observation "microinvasion cannot be ex-
cluded" within the High-Grade Squamous Intraepithelial
Lesion category (HSIL) [4].
The Brazilian Guidelines for Cervical Cancer Screening
aim to standardize recommendations for proper care of
women identified as possible carriers of preinvasive or
invasive lesions.
For patients with a Pap smear indicating HSIL-micro,
the recommendation is immediate referral to a second-
ary care unit for colposcopy. When colposcopy shows
no lesion or the findings are not suggestive of invasion,
the recommended approach is excision of the trans-
formation zone (ETZ), according to its location [5]. If
changes suggestive of invasion are present, one or more
biopsies including representative specimens of the le-
sion should be submitted to further analysis.
This approach is more invasive than that recom-
mended to women with HSIL report, in which some in-
vestigative procedures are necessary before an excisional
procedure, when major findings are not seen.
However, the recommendation for women with diag-
nosis of HSIL-micro is based on expert opinion, since
there is no information on the risk of preinvasive or in-
vasive lesions in women with this cytological diagnosis.
The purpose of this study is to estimate the risk,
through prevalence ratio (PR), of preinvasive and inva-
sive lesions in women with HSIL-micro Pap smear
reports compared with those with HSIL. In other words,
since patients with a cytologic result of HSIL-micro
must be submitted to ETZ, our aim is to find out
whether the histological results of these patients signifi-
cantly differ from those of patients with HSIL cytology
in order to support this more invasive approach.
Methods
Study design
A cross-sectional study with women identified in the
SITEC database (National Cancer Institute Technological
Integrated Service in Cytology), which examines all Pap
smear samples from women visiting primary care units in
the city of Rio de Janeiro (RJ, Brazil). Data were obtained
from medical records.
Subjects
The study located all women with HSIL-micro report in cy-
tologic exams obtained between June 2006 and December
2012 and who were referred and assisted in one of the
collaborating secondary units: Instituto Nacional de Saúde
da Mulher, da Criança e do Adolescente Fernandes Fig-
ueira, Fundação Oswaldo Cruz (IFF/Fiocruz), Rio de
Janeiro, Brazil (IFF/Fiocruz, RJ, Brazil) and Instituto Nacio-
nal do Câncer José Alencar Gomes da Silva (Inca, RJ,
Brazil). Pregnant women and patients with some type of
immunodeficiency were excluded. For each patient in-
cluded with HSIL-micro diagnosis, four patients with HSIL
cytologic diagnosis referred and assisted in one of these
units were included: two diagnosed immediately before and
two immediately after each diagnosis of HSIL-micro.
Variables and outcomes
Information related to the investigation and final diagno-
ses were obtained from medical records of the included
patients. We searched for patient characteristics (age,
number of gestations, number of child births) colposcopic
findings, performed procedures and final histological or
follow-up diagnosis.
Statistical analysis
Descriptive analyses were performed to estimate frequen-
cies, profiles and identify outliers. Bivariate analyses were
performed to estimate association between Pap smear and
final diagnosis. Excel® was used to create the database and
SPSS® to perform the statistical analysis. Student’s t-test was
used to analyze numerical variables. Chi-square test or Fish-
er's exact test were used for categorical variables. All analyses
were performed considering the confidence level of 95 %.
Ethical issues
This study was approved and informed consent waived by
the ethics committees of the IFF/Fiocruz and Inca under
protocol numbers 213.239 and 132/12, respectively.
Results
Between June 2006 and December 2012, 96,855 Pap
smears were analyzed by SITEC. Among these, 4,581
were referred to Inca and IFF/Fiocruz, the colposcopic
units participating in our study.
We identified 318 patients with HSIL-micro cytologic
diagnosis, of whom 68 were referred to the following
collaborating units: 17 to IFF/Fiocruz and 51 to Inca in
this period of time (Fig. 1). Out of these, 15 and 38 pa-
tients, respectively, were actually received at the units.
The 15 patients received at IFF/Fiocruz were included in
the study. Of the 38 patients received at Inca, six were
excluded (one tested positive to Human Immunodefi-
ciency Virus - HIV - and five did not conclude the diag-
nostic investigation). Therefore, thirty-two women were
included in the study. To compose the comparison
group, 60 cases of HSIL were included at IFF/Fiocruz
and 128 at Inca (a 4:1 HSIL:HSIL-micro ratio, to in-
crease study power).
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Fig. 1 Flowchart of the study
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The sample characteristics are described in Table 1.
The mean age was 49.78 years for patients with HSIL-
micro cytologic report and 34.36 years for patients with
a HSIL report (p <0.0001). There were also differences
in parity: in the first group, patients had an average of
4.56 pregnancies and 3.82 deliveries compared to an
average of 2.68 pregnancies and 2.27 deliveries in the
second group (p = 0.018 and 0.006, respectively).
In the HSIL-micro group, 31.9 % of patients had major
findings and 12.8 % had findings suggestive of invasion
on colposcopic examination. In the HSIL group, major
findings were found in 35.6 % and no cases had findings
suggestive of invasion. There was a significant difference
between groups regarding visualization of the squamous
columnar junction (SCJ). In 29.8 % of patients with
cytological report of HSIL-micro the SCJ was not visible,
while 10.1 % of patients with cytological report of HSIL
had a non-visible SCJ (Table 1).
The final diagnoses revealed a frequency of preinvasive
lesions (Cervical Invasive Neoplasia - CIN - 2–3 or
adenocarcinoma in situ - AIS) of 31.9 % (15/47) and
59.6 % (112/188) in patients with HSIL-micro and HSIL,
respectively, while the frequency of invasive disease (IA1
cancer, invasive cancer and adenocarcinoma) was 63.8 %
(30/47) and 11.7 % (22/188), respectively (Table 2).
Table 3 shows the distribution of the final diagnoses
recategorized as cancer or preinvasive lesions (CIN 2–3 or
AIS) and the absence of these diagnoses (CIN 1, Human
Papilloma Virus - HPV - cytopathic effect and negative re-
sults) by cytological diagnosis (HSIL-micro versus HSIL).
In the HSIL-micro group, 95.7 % (45) had either preinva-
sive or invasive disease, while in the HSIL group, 72.3 %
(136) had one of these lesions. There was a significant dif-
ference between groups (p < 0.0001), the HSIL-micro
group had a prevalence of preinvasive or invasive disease
6.5 times (95 % CI = 1.6-5.7) higher than the HSIL group.
Table 4 shows a similar analysis, but correlating the
cytologic diagnosis with presence or absence of invasive
lesion in comparison with non-invasive lesions or no
lesions at all. In the HSIL-micro group, 63.8 % (30) had
cancer as a final diagnosis. In the HSIL group, 11.7 %
(22) had a final diagnosis of cancer. There was also a
significant difference between groups (p < 0.0001), the
HSIL-micro group showed prevalence of invasive disease
2.4 times (95 % CI = 1.7-3.6) higher than HSIL group.
Table 1 Sample characteristics (IFF/Fiocruz-INCA, RJ, Brazil,
2006–2012)
Characteristic HSIL micro HSIL Total p-value
N (%) 47 (20) 188 (80) 235 (100) -
Age (mean, SD) 49.78 (14.44) 34.36 (11.84) 37.44 (13.83) <0.001a
Number of
pregnancies
4.56 (4.05) 2.68 (1.94) 3.14 (2.71) <0.018a
Parity 3.82 (3.53) 2.27 (1.76) 2.60 (2.34) <0.006a
Follow-up unit n (%)
IFF 15 (31.9) 60 (31.9) 75 (31.9) 0.999
INCA 32 (68.1) 128 (68.1) 160 (68.1)
Colposcopic findings
n (%)
Normal 3 (6.4) 12 (6.4) 15 (6.4)
Minor abnormal
findings (grade 1)
2 (4.3) 25 (13.3) 27 (11.5)
Major abnormal
findings (grade 2)
15 (31.9) 67 (35.6) 82 (34.9) <0.001
Suspicious for
invasion
6 (12.8) 0 (0) 6 (2.6)
Not reported 21 (44.7) 84 (44.7) 105 (44.7)
View of SCJb n (%)
Visible SCJ 6 (12.8) 61 (32.4) 33 (14)
Non visible or
partially visible SCJ
14 (29.8) 19 (10.1) 67 (28.5) <0.001c
Not reported 27 (57.4) 108 (57.4) 135 (57.4)
Procedure n (%)
None 0 (0) 16 (8.5) 16 (6.8)
Biopsy 19 (40.4) 43 (22.9) 62 (26.4)
Type 1 excisiond 7 (14.8) 102 (54.3) 109 (46.4) <0.001
Type 3 excisione 15 (31.9) 22 (11.7) 37 (15.7)
Not reported 5 (10.6) 5 (2.6) 10 (4.3)
aStudent's t-Test
bSquamous Columnar Junction
cChi-square test (excluded cases with no data)
d, eUsing Large Loop or Straight Wire Excision of the Transformation Zone
Table 2 Final diagnoses obtained from each group
(IFF/Fiocruz-INCA, RJ, Brazil, 2006–2012)
Pap smear diagnosis n (%) Total
Final diagnosisa HSIL microh HSILc p-value
Negative 0 (0) 24 (12.8) 24 (10.2) 0.005
LSILb 2 (4.3) 28 (14.9) 30 (12.8) 0.052
HSILc 15 (31.9) 112 (59.6) 127 (54) <0.001
AISd 0 (0) 2 (1.1) 2 (0.9) 1.000
Microinvasive lesione 6 (12.8) 10 (5.3) 16 (6.8) 0.070
Invasive lesionf 19 (40.4) 9 (4.8) 28 (11.9) <0.001
Adenocarcinomag 5 (10.6) 3 (1.6) 8 (3.4) 0.009
Total (%) 47 (100) 188 (100) 235 (100)
aDiagnoses obtained at the end of investigation considering histopathological
specimens. Negative cases were based on absence of visible colposcopic
findings and two negative cytopathologic exams with a minimum of
six-month intervals
bLow-grade squamous intraepithelial lesion (includes cytopathic effect by HPV
and CIN 1)
cHigh-grade squamous lesion (includes CIN 2 and CIN 3)
dAdenocarcinoma in situ
eMicroinvasive squamous carcinoma of the cervix
fInvasive squamous carcinoma of the cervix
gInvasive squamous adenocarcinoma of the cervix
hHigh-grade intraepithelial lesion cannot exclude microinvasion
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Discussion
The search for information published at PubMed, Cielo,
Embase and Lilacs databases, concerning the prevalence
of preinvasive or invasive disease in the presence of HSIL-
micro cytological diagnosis, proved to be unsuccessful at a
national and international level. The terms used in these
searches were “Cervical Intraepithelial Neoplasia” and
“Papanicolaou Test” and either one of the following:
“HSIL microinvasion”, “microinvasion”, “cannot exclude
microinvasion”, “cannot exclude micro invasion” or “can-
not exclude invasion”. As no scientific article was found
on this cytological diagnosis, it was not possible to make a
direct comparison between our results and those from
other authors.
In this study, women presenting HSIL in Pap smear re-
sults had preinvasive lesions in 60.7 % of the cases. Adding
such results to the invasive lesion cases, the percentage of
both lesions reached up to 72.3 %. This percentage is simi-
lar to that described in the medical literature, which is
about 70 % [6].
Still, Massad et al. [7] studied the correlation between
cytologic and histologic diagnoses, and found in women
with HSIL cytologic results, 47.8 % of CIN 2 or 3 and
5 % of cancer. This lower percentage may be explained
by the difference in women’s age, since the mean age of
women included in their study was lower than that
found in our study (33 vs. 37.4 years old) [7].
The frequency of invasive disease in women with HSIL
in our study was 11.7 % (22/188), which is much higher
than the numbers reported by Massad et al. [7], who
found it in 5 % of their sample. Other studies mention
higher frequencies of CIN2-3 in women with a Pap
smear report of HSIL [8–11]. These frequencies depend
upon the prevalence of preinvasive disease in the popu-
lation and may explain the discrepancies observed in dif-
ferent studies.
Our higher frequency of invasive and pre invasive dis-
ease can be explained by the fact that the screening pro-
gram in Brazil is opportunistic. Although the screening
is offered to all women between 25 (if sexually active)
and 64 years old, controlling underscreened women is
impossible due to the current lack of a population-based
information system [2].
However, in women with HSIL-micro cytologic reports,
preinvasive and invasive diseases were present in 31.9 %
and 63.8 % of them, respectively. These findings show that
nearly all women with this cytologic diagnosis (95.7 %)
have a significant disease and require investigation and
treatment, reinforcing the recommendation of excisional
procedures in such cases. Although it is not possible to
make a direct comparison of these values with data from
other publications, we consider these findings quite reli-
able and generalizable to a similar sample.
The prevalence ratio of invasive disease and preinvasive
plus invasive lesions in the HSIL-micro group compared
with the HSIL group was 2.41 and 6.5, respectively, show-
ing that the former actually points to a greater risk of
significant disease.
Although the number of pregnancies, parity, visibil-
ity of SCJ and performed procedure were statistically
related to the cytological report, these factors are
interrelated and age-related, as older women tend to
have more children, their SCJ tend to be endocervical
and, as a consequence, more type 3 excisions are
expected to be performed. Similarly, colposcopic find-
ings are proxies of the outcome itself and cannot act
as a confounder (Table 1).
The referral unit, another possible confounder due to
differences in routine care was not significantly related
to the cytological report (Table 1).
We analyzed age as a possible confounder, but the dif-
ferences between age groups were not significant, due to
the small number of patients in some age ranges (data
not shown).
Table 3 Prevalence of preinvasive or invasive disease by study














HSIL-Microd 45 2 47 6.5 (1.6 - 25.7)
HSILe 136 52 188 <0.001
Total 181 54 235
aRecategorized diagnoses obtained at the end of investigation considering
histopathological specimens. Negative cases were based on absence of visible
colposcopic findings and two negative cytopathologic exams with a minimum
of six-month intervals
bIncludes CIN 2, CIN 3, adenocarcinoma in situ and microinvasive or invasive
squamous carcinoma of the cervix
cIncludes negative diagnoses, HPV cytopathic effect and CIN 1
dHigh-grade intraepithelial lesion cannot exclude microinvasion
eHigh-grade intraepithelial lesion
Table 4 Prevalence of invasive disease by study group










(PR) (CI 95 %)
Pap smear
diagnosis
HSIL-microd 30 17 47 2.4 (1.7 – 3.6)
HSILe 22 166 188 <0.001
Total 52 183 235 -
aRecategorized diagnoses obtained at the end of investigation considering
histopathological specimens. Negative cases were based on absence of visible
colposcopic findings and two negative cytopathologic exams with a minimum
of six-month intervals
bIncludes microinvasive squamous carcinoma of the cervix
cIncludes negatives, CIN 1, 2 or 3, or AIS
dHigh-grade intraepithelial lesion cannot exclude microinvasion
eHigh-grade intraepithelial lesion
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Conclusion
The higher frequency of preinvasive and invasive lesions
in women with cytologic diagnosis of HSIL-micro rein-
forces recommendations for immediate investigation.
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